CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
Secukinumabbiological
Likely dose
Secukinumab 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04717466
NCT04717466Phase 4Completed
CompareCT.gov

Brain Morphological Changes Accompanied by Effective Biologic Treatments for Psoriasis and Their Associations With the Improvement of Well-being, Itch, and Pain

University of Miami·interventional·Posted Jan 22, 2021·Updated Jun 5, 2025

In Brief

A Phase 4 clinical trial evaluating Secukinumab for Psoriasis and Healthy. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the effect of a biologic drug targeting the Interleukin (IL)-17 pathway (secukinumab) on brain plasticity and examine whether the plastic changes correlate with the improvement of perception of well-being, itch, and pain in participants with psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis, Healthy
CountriesUnited States
CollaboratorsNovartis

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedJan 22, 2021
Enrollment StartJun 29, 2021
Primary CompletionMay 16, 2024
Study CompletionMar 4, 2025
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 5.4 years ago

Interventions

Secukinumabbiological

300mg subcutaneous injection